Valeant Pharmaceuticals International (NYSE:VRX)

CAPS Rating: 4 out of 5

A global specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products, primarily in the areas of neurology, infectious disease, and dermatology.

Results 1 - 20 of 47 : 1 2 3 Next »

Recs

0
Member Avatar moneyman999 (41.49) Submitted: 2/15/2015 1:44:00 AM : Underperform Start Price: $168.17 VRX Score: -19.39

Simply overvalued,volitilty will be high but gains will be low.

Recs

0
Member Avatar freecapital (74.59) Submitted: 2/10/2015 11:37:21 PM : Outperform Start Price: $162.74 VRX Score: +21.99

Donville

Recs

0
Member Avatar 10x2 (57.37) Submitted: 1/30/2015 8:17:37 PM : Outperform Start Price: $158.00 VRX Score: +23.18

Sabrient pick.

Recs

0
Member Avatar reddingrunner (96.23) Submitted: 1/16/2015 1:33:28 PM : Outperform Start Price: $155.58 VRX Score: +24.53

sabrient bakers dozen 2015

Recs

0
Member Avatar 1russianguy (84.89) Submitted: 1/15/2015 9:17:14 AM : Outperform Start Price: $158.00 VRX Score: +23.18

Sabrient

Recs

0
Member Avatar mrudolph72 (63.03) Submitted: 1/14/2015 3:10:34 PM : Outperform Start Price: $157.00 VRX Score: +23.33

Sabrient

Recs

0
Member Avatar Defshark82 (72.15) Submitted: 12/31/2014 11:46:13 AM : Outperform Start Price: $143.88 VRX Score: +38.54

top pick JPM tracker

Recs

0
Member Avatar mlarms (< 20) Submitted: 7/31/2014 2:24:29 AM : Outperform Start Price: $118.88 VRX Score: +61.24

My big Pharma pick

Recs

0
Member Avatar TerryHoodSr (79.83) Submitted: 6/16/2014 10:58:46 AM : Outperform Start Price: $117.81 VRX Score: +62.09

VRX EPS 1YR 60% 3YR 50% 5YR 55%
CURR EPS 2.89 NEXT YR EPS 10.54
NEXT YR PE 11

Recs

0
Member Avatar chipotlepickle (98.41) Submitted: 6/15/2014 5:21:26 PM : Underperform Start Price: $118.81 VRX Score: -60.41

Running out of one time events.

Recs

0
Member Avatar ValueSwap (< 20) Submitted: 6/12/2014 3:29:27 PM : Outperform Start Price: $120.02 VRX Score: +58.44

How R&D should work and their aggressive capitalizing interest to generate a low tax rate create much fuzz about the company, which in turn give a long term holder a good entry point

Recs

0
Member Avatar IanERichards (84.98) Submitted: 6/4/2014 7:37:57 AM : Outperform Start Price: $131.15 VRX Score: +43.96

Focus on capital allocation - creative approach to making a deal

Recs

0
Member Avatar RickP (89.66) Submitted: 5/18/2014 6:17:33 PM : Outperform Start Price: $125.85 VRX Score: +47.59

Great CEO......

Fantastic future regardless of whether Allergen merger occurs or not

Recs

0
Member Avatar RLBOWERSOX (97.61) Submitted: 3/31/2014 4:40:45 PM : Outperform Start Price: $132.07 VRX Score: +40.14

One of the final four

Recs

0
Member Avatar mrwrong (< 20) Submitted: 3/29/2014 2:06:48 PM : Underperform Start Price: $129.27 VRX Score: -42.82

growth will stall as company comes a cropper, with a bridge too far. most all- do, but i like it now.

Recs

0
Member Avatar motto1628 (52.81) Submitted: 3/25/2014 4:05:57 PM : Outperform Start Price: $132.26 VRX Score: +39.58

- genius CEO in acquisition
- diversified pharmaceutical products
- stock advisor pick

Recs

0
Member Avatar mtbound (43.31) Submitted: 3/1/2014 12:25:37 PM : Outperform Start Price: $143.30 VRX Score: +26.66

I'm here mainly because of leadership. I've bought in to extraordinary leadership extracting value.

Recs

0
Member Avatar lapinkpanther (67.76) Submitted: 2/24/2014 2:58:06 PM : Outperform Start Price: $145.96 VRX Score: +24.69

Great Management!

Recs

0
Member Avatar bradrimm (65.10) Submitted: 2/9/2014 9:55:01 AM : Outperform Start Price: $138.21 VRX Score: +28.65

Strips dead wood. Value adding. Good macro scene

Recs

0
Member Avatar ejlanders14 (< 20) Submitted: 1/24/2014 11:02:41 PM : Underperform Start Price: $132.48 VRX Score: -34.44

Hmmm...on the balance sheet, MF shows "intangibles" rose 8-fold from 2009 to 2013...really?

Results 1 - 20 of 47 : 1 2 3 Next »

Featured Broker Partners


Advertisement